Source comparison
BPC-157 Crohn's Disease Research Mechanism: Study Comparison
World J Gastroenterol (2017) TNBS-induced colitis (rats) 10 μg/kg IP Histological damage score 58% reduction in inflammation VEGF upregulation, mucosal healing Strong evidence for tissue repair without immunosuppression. Dose-response curve established J Physi
This comparison does not assign a generated winner or score.
- World J Gastroenterol (2017)
- TNBS-induced colitis (rats)
- 10 μg/kg IP
- Histological damage score
- 58% reduction in inflammation
- VEGF upregulation, mucosal healing
- Strong evidence for tissue repair without immunosuppression. Dose-response curve established
- J Physiol Pharmacol (2020)
- DSS chronic colitis (mice)
- Fecal calprotectin, crypt architecture
- 40% lower calprotectin, improved histology
- Tight junction protein expression, reduced permeability
- Chronic model more relevant to human Crohn's. Results sustained over 21 days
- Eur J Pharmacol (2018)
- TNBS colitis (rats)
- 10 μg/kg IP + oral
- Microvessel density, ulcer size
- 47% higher capillary density, 63% ulcer reduction
- VEGFR2 activation, angiogenesis
- Dual administration route tested. Oral showed partial efficacy, IP superior
- Dig Dis Sci (2016)
- Acetic acid colitis (rats)
- 10 μg/kg gastric
- Macroscopic damage score
- 54% reduction in lesion area
- Nitric oxide modulation, reduced oxidative stress
- Early-stage evidence. Acetic acid model less clinically relevant than TNBS/DSS